Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.00) by Infinity percent. This is a 116.67 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $83.127 million which beat the analyst consensus estimate of $79.992 million by 3.92 percent. This is a 38.27 percent increase over sales of $60.119 million the same period last year.